EarningsQ2 2026 Earnings Report
MX:CMPSN Q2 2026 EPS Results
Actual EPS-$34.14
Consensus EPS-$7.05
Beat/MissMissed by -$27.10
One Year Ago EPS-$7.45
MX:CMPSN Q2 2026 Revenue Results
Actual Revenue$0.00
Expected Revenue$0.00
Beat/MissMet expectations
YoY Revenue Growth―
Earnings Announcement Details
QuarterQ2 2026
Date08/05/2026
TimeBefore Open
Conference CallWednesday, August 5, 2026
MX:CMPSN Upcoming Earnings
COMPASS Pathways's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:CMPSN Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong clinical and commercial momentum: highly statistically significant Phase III efficacy, demonstrated 6-month durability, a generally favorable safety profile, an active rolling NDA with modules under review, a healthy cash position ($433M) through 2028, extensive commercial hiring, strong prescriber interest (~90% willing to prescribe), and substantial launch planning (training, payer engagement, partnerships). Key risks highlighted are timing and sequencing uncertainties around DEA rescheduling and REMS finalization, ongoing payer negotiations, remaining 52-week safety data submission, and potential competitive entrants. On balance, the positive clinical results and robust launch preparedness materially outweigh the timing and regulatory uncertainties.Company Guidance
Statistically Significant Phase III Results
COMPASS reported highly statistically significant positive primary endpoint readouts from two Phase III trials for COMP360, with demonstrated rapid onset (as quickly as 1 day) and durability sustained through at least 6 months.
Safety and Tolerability Profile
The totality of clinical data to date shows COMP360 has a generally well tolerated and safe profile; integrated safety analyses are being prepared from blinded 26-week data and full 52-week safety data will be provided to regulators.
NDA Rolling Submission Underway; Q4 Completion Expected
COMPASS is executing a rolling NDA submission to the FDA, with some modules already under review and an expected completion of the filing in the fourth quarter of 2026; potential for accelerated approval was highlighted.
Strong Balance Sheet
Cash on hand of $433 million as of June 30, 2026, which management states carries the company well through launch and into 2028.
Commercial Readiness and Talent Hiring
Commercial leadership team fully hired, with direct reports from J&J, Gilead, Otsuka, and Axsome who collectively have led over 70 product launches; salesforce recruiting has been initiated to support launch.
High Prescriber Interest
Prescriber-focused market research showed ~90% of interventional psychiatrists stated they would prescribe COMP360 within the first year of availability, described as an unusually high willingness-to-prescribe rate.
Established Site Infrastructure to Support Launch
COMPASS plans to leverage the existing interventional psychiatry infrastructure (noted as more than 8,000 established U.S. sites) that support multi-hour monitored treatments such as Spravato, TMS, and ECT.
Strategic Collaborations and Partnerships
Expanded strategic collaborations (total of 8, including Radial and Osmind) to support launch priorities like patient experience, distribution, and operational readiness.
Patient Market Opportunity
Management highlighted a target patient population of approximately 4 million people living with treatment-resistant depression (TRD) in the U.S., framing COMP360 as a potential blockbuster opportunity.
Operational Launch Preparations
Planned deployment of a field reimbursement team, market access outreach to payers with positive early feedback, REMS planning, training grants with third parties, and continued real-world evidence and IIS activity to support future indications.
PTSD and Other Indications in Development
PTSD Phase II/III study (300 patients, capped ~15% military/VA-related enrollment) is underway; company restarting investigator-initiated studies (IIS) and exploring additional indications such as AUD and OCD.
Evidence on Patient Experience Monitoring
Post-hoc analysis indicates ~80% of administration sessions in certain studies were silent, supporting the concept of an inner-directed psilocybin experience and potential flexibility in who monitors sessions.
MX:CMPSN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed